-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BeiGene is a global biotechnology company focusing on the development and commercialization of innovative drugs worldwide
.
The company today announced the recommendation by the Independent Commission data detection, one used to evaluate the anti-PD-1 antibody Chak one hundred ® (natalizumab for Rayleigh) in combination with chemotherapy, compared to placebo in combination with chemotherapy as a treatment for recurrent or metastatic The Phase 3 RATIONALE 309 clinical trial of first-line therapy for patients with sexual nasopharyngeal carcinoma reached its primary endpoint in an interim analysis
Baiji Divine tumor immunology Chief Medical Officer Ben Yong, MD, commented: "We are very excited to be observed in this Phase 3 clinical trials, one hundred Chak ® in combination with chemotherapy in patients with nasopharyngeal carcinoma capable of progression-free survival brought improve clinically significant
.
this indicates that the positive results obtained in item 5 percentage Chak ® 3 clinical trials, we are also an extensive clinical program of anti-PD-1 antibody for this potential difference to assess
BeiGene plans to communicate the results of the trial with multiple regulatory agencies and announce the data at an upcoming medical conference
.
One hundred ZeAn ® combination chemotherapy vs Placebo combination chemotherapy for the treatment of recurrent or metastatic NPC patients RATIONALE 309 Clinical Trial
RATIONALE 309 was a randomized, double-blind, placebo-controlled Phase 3 clinical trial (NCT03924986), was to compare one hundred Chak ® in combination with gemcitabine and cisplatin versus placebo in combination with gemcitabine and cisplatin as first-line therapy for recurrent or metastatic NPC Effectiveness and safety
.
The primary endpoint of the trial is the PFS assessed by the IRC in the ITT population; key secondary endpoints include overall survival (OS), objective response rate (ORR) and duration of response (DoR) as assessed by IRC, as well as assessment by the investigator PFS